These ads enable local businesses to reach their target audience – the local community

It is important that we keep promoting these ads as our local businesses need as much support as possible during these challenging times

An agreement has been reached to support the manufacture of up to 60 million doses of the Novavax coronavirus vaccine in the UK

The pharmaceutical company GlaxoSmithKline (GSK) will provide filling and finishing capacity at its Barnard Castle facility in the north-east of England in May

Boris Johnson said the deal between GSK, Novavax and the UK government’s vaccine task force will “push our vaccine rollout further”

“Fill and Finish” is the final stage of vaccine manufacture, where vials of the final vaccine are prepared and packaged for distribution and use

GSK’s Barnard Castle facility is a specialized facility in GSK’s global manufacturing network that supports the production of GSK pharmaceutical and vaccine products

The UK government has secured 60 million doses of the vaccine under a pre-sale agreement with Novavax

The protein antigen component of NVX-CoV2373 is also manufactured in North East England by Novavax’s manufacturing partner FUJIFILM Diosynth Biotechnologies at its Billingham, Stockton-on-Tees site

Mr Johnson said, “I am pleased with GSK’s investment, which shows the strength of UK manufacturing and will further fuel our vaccine adoption

“The Vaccines Task Force has worked hand in hand with business to successfully deliver vaccines across the UK and this agreement will continue to support our approach

“We are on the right track to address everyone over 50 by age 15 April and all adults to offer a first prick by the end of July, and once again I want to encourage everyone to sign up for a vaccine when they call you””

Roger Connor, President of GSK Vaccines, said, “GSK is pleased to be supporting Novavax and the UK Vaccine Task Force with this UK manufacturing agreement, and our Barnard Castle facility is now doing the rapid preparatory work required for the Production of up to 60 vaccines requires millions of doses of this vaccine

“We have made sure that we can deliver these quantities without affecting the supply of our other vital drugs and vaccines and without disrupting the other Covid-19 collaborations in which GSK is involved worldwide”

Earlier this month, the company behind the Novavax sting announced that it was 86% effective against the Kent variant and 96% effective against cases caused by the original strain of the coronavirus

According to the results of the UK Phase 3 study, the sting provides 100% protection from serious illness, including all hospital admissions and deaths

This website and associated newspapers adhere to the Code of Conduct of the Editors of the Independent Press Standards Organization.If you have a complaint about any editorial content that relates to inaccuracies or tampering, please contact the editor here if you have a complaint about If you are not satisfied with the answer, you can contact IPSO here

© Copyright 2001-2021 This site is part of Newsquest’s Verified Local Newspaper Network A Gannett Company Newsquest Media Group Ltd, Loudwater Mill, Station Road, High Wycombe, Buckinghamshire HP10 9TY | 01676637 | Registered in England & Wales


World News – GB – GSK in support of Novavax manufacture of Covid-19 stab at Barnard Castle